Posted from: Tuesday, November 25, 2014 - 03:30 PM - Present

New Indications for Cyramza

November 5, 2014 – Cyramza® (ramucirumab — Lilly), originally FDA-approved in April 2014 as monotherapy to treat patients with certain stomach cancers, is used as second-line therapy for advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma that have progressed despite or during chemotherapy with a platinum-based or fluoropyrimidine drug.  In early November, Cyramza received new indications for the same conditions, but in combination with paclitaxel, also a cancer drug.  


Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Prices referenced are estimates based on available data and are subject to change at the time a claim is processed. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information purposes only.  The reference to any medication above does not imply that the medication is covered by your plan.

Last Updated Friday, October 18, 2019 - 02:22 AM.